Astellas Pharma Faces Currency Losses in FY2024

Astellas Pharma (JP:4503) has released an update.

Astellas Pharma Inc. reported a foreign exchange loss of ¥12.2 billion for the first half of FY2024, following fluctuations in currency rates that led to a significant loss in the second quarter despite gains in the first quarter. These financial results highlight the impact of currency valuations on the company’s monetary assets and liabilities.

For further insights into JP:4503 stock, check out TipRanks’ Stock Analysis page.